CPC C07K 16/2866 (2013.01) [C07H 21/04 (2013.01); C07K 16/28 (2013.01); C12N 15/09 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); A61P 13/12 (2018.01); C07K 14/521 (2013.01); C07K 14/7158 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/30 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01)] | 20 Claims |
1. A nucleic acid molecule encoding a polypeptide comprising an anti-CX3 chemokine receptor 1 (CX3CR1) immunoglobulin single variable domain and a half-life extending moiety, wherein said anti-CX3CR1 immunoglobulin single variable domain consists essentially of four framework regions (FR1, FR2, FR3 and FR4) and three complementary determining regions (CDR1, CDR2 and CDR3), wherein:
i) said CDR1 has the amino acid sequence of SEQ ID NO: 146;
ii) said CDR2 has an amino acid sequence that a) has at least 90% amino acid identity with the amino acid sequence of SEQ ID NO: 176 or b) has the amino acid sequence of SEQ ID NO: 176 or SEQ ID NO: 177; and
iii) said CDR3 has the amino acid sequence of SEQ ID NO: 191.
|